Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 2
1958 1
1981 1
1982 4
1983 6
1984 8
1985 5
1986 15
1987 10
1988 9
1989 21
1990 21
1991 17
1992 14
1993 19
1994 25
1995 10
1996 9
1997 18
1998 13
1999 16
2000 20
2001 24
2002 17
2003 19
2004 31
2005 32
2006 41
2007 34
2008 26
2009 23
2010 27
2011 26
2012 27
2013 27
2014 22
2015 15
2016 15
2017 22
2018 20
2019 19
2020 22
2021 21
2022 22
2023 16
2024 19
2025 20
2026 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

796 results

Results by year

Filters applied: . Clear all
Page 1
Etodolac.
[No authors listed] [No authors listed] 2025 Jul 20. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2025 Jul 20. LiverTox®: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643997 Free Books & Documents. Review.
Etodolac is a nonsteroidal antiinflammatory drug (NSAID) that is available by prescription only and is used long term for therapy of chronic arthritis and short term for acute pain. Etodolac has been linked to rare instances of clinically apparent drug induced liver …
Etodolac is a nonsteroidal antiinflammatory drug (NSAID) that is available by prescription only and is used long term for therapy of …
Etodolac clinical pharmacokinetics.
Brocks DR, Jamali F. Brocks DR, et al. Clin Pharmacokinet. 1994 Apr;26(4):259-74. doi: 10.2165/00003088-199426040-00003. Clin Pharmacokinet. 1994. PMID: 8013160 Review.
Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. ...The area under the plasma concentration-time curve of racemic etodolac increases linearly with doses used clinically. The elimination half-life of etodolac is …
Etodolac is a chiral nonsteroidal anti-inflammatory drug (NSAID) that is marked as the racemate. ...The area under the plasma concent …
Etodolac utility in osteoarthritis: drug delivery challenges, topical nanotherapeutic strategies and potential synergies.
Gaddala P, Choudhary S, Sethi S, Sainaga Jyothi VG, Katta C, Bahuguna D, Singh PK, Pandey M, Madan J. Gaddala P, et al. Ther Deliv. 2024;15(12):977-995. doi: 10.1080/20415990.2024.2405456. Epub 2024 Sep 30. Ther Deliv. 2024. PMID: 39345034 Free PMC article. Review.
Emphasis is placed on the pivotal role of etodolac in OSA management, supported by both preclinical and clinical evidences in topical drug delivery. ...Integration of artificial neural network (ANN) techniques with nanotechnology approaches emerges as a promising strategy …
Emphasis is placed on the pivotal role of etodolac in OSA management, supported by both preclinical and clinical evidences in topical …
Etodolac-induced erythroderma.
Seara V, Costa-Fernandes S, Duarte M, Maia L. Seara V, et al. Dermatol Online J. 2021 Nov 15;27(11). doi: 10.5070/D3271156099. Dermatol Online J. 2021. PMID: 35130411 Free article. No abstract available.
Pharmacokinetics of sustained-release etodolac.
Benet LZ. Benet LZ. Rheumatol Int. 1993;13(2 Suppl):S3-5. doi: 10.1007/BF00290277. Rheumatol Int. 1993. PMID: 8210922 Review.
The extensive kinetic/dynamic characterization of etodolac, together with its short half-life, makes the drug an ideal candidate for a sustained-release (SR), once-a-day formulation. ...Simulation analyses for etodolac SR suggest that PID responses are maintained ov …
The extensive kinetic/dynamic characterization of etodolac, together with its short half-life, makes the drug an ideal candidate for …
Etodolac: analgesic effects in musculoskeletal and postoperative pain.
Pena M. Pena M. Rheumatol Int. 1990;10 Suppl:9-16. doi: 10.1007/BF02274750. Rheumatol Int. 1990. PMID: 2150571 Review.
Numerous clinical trials have shown etodolac to be an effective analgesic. The purpose of the present report is to review results of 14 studies that demonstrate the effectiveness of etodolac in a variety of painful conditions. ...The efficacy of etodolac was …
Numerous clinical trials have shown etodolac to be an effective analgesic. The purpose of the present report is to review results of …
Etodolac: efficacy in osteoarthritis and effects on chondrocyte function.
Bacon PA. Bacon PA. Rheumatol Int. 1990;10 Suppl:3-7. doi: 10.1007/BF02274749. Rheumatol Int. 1990. PMID: 2150570 Review.
The clinical and biochemical effects of etodolac, a new NSAID, on the symptoms of OA and on cartilage metabolism are reviewed. Clinically, etodolac (200-600 mg/day) was more effective than placebo, and as effective as aspirin (3200-4800 mg/day), piroxicam (20 mg/day …
The clinical and biochemical effects of etodolac, a new NSAID, on the symptoms of OA and on cartilage metabolism are reviewed. Clinic …
Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.
Balfour JA, Buckley MM. Balfour JA, et al. Drugs. 1991 Aug;42(2):274-99. doi: 10.2165/00003495-199142020-00008. Drugs. 1991. PMID: 1717225 Review.
Etodolac also provides relief of other types of pain, including that arising from gouty conditions and traumatic injury. In all indications, etodolac appears to be at least as effective as other NSAIDs. The incidence of clinical adverse effects other than abdominal …
Etodolac also provides relief of other types of pain, including that arising from gouty conditions and traumatic injury. In all indic …
A review of the antiarthritic efficacy and safety of etodolac.
Zvaifler N. Zvaifler N. Clin Rheumatol. 1989 Mar;8 Suppl 1:43-53. doi: 10.1007/BF02214109. Clin Rheumatol. 1989. PMID: 2525982 Review.
A review of the literature on numerous clinical studies showed that etodolac (200 to 600 mg/day) is effective in the treatment of osteoarthritis and rheumatoid arthritis. Etodolac has also been shown to be very well tolerated. In double-blind studies, there were no …
A review of the literature on numerous clinical studies showed that etodolac (200 to 600 mg/day) is effective in the treatment of ost …
Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies.
Lanza FL, Arnold JD. Lanza FL, et al. Clin Rheumatol. 1989 Mar;8 Suppl 1:5-15. doi: 10.1007/BF02214105. Clin Rheumatol. 1989. PMID: 2525983 Review.
In contrast, the greatest mean daily increase in blood loss with etodolac therapy was 0.2 ml. In a 4-week study of etodolac (600 and 1000 mg/day) and piroxicam (20 mg/day) given to patients with osteoarthritis or rheumatoid arthritis, blood loss seen with etodola …
In contrast, the greatest mean daily increase in blood loss with etodolac therapy was 0.2 ml. In a 4-week study of etodolac (6 …
796 results